Insider buying last 90 days
No open-market insider purchases were filed for BAX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Baxter International shares have been volatile this week, swinging between gains and losses across choppy sessions, with the stock recently outperforming or underperforming the broader market on different days amid a generally negative tape for the S&P 500 and Dow. Barclays maintained its Underweight rating on the stock but raised its price target to $23 from $20, a move it frames against a closing price of $25.79. The company's Q3 2026 results, reported 29 October, showed global sales of approximately $3 billion, up 5% on both reported and organic bases, with adjusted EPS of $0.58 beating the $0.52 estimate, led by Advanced Surgery, Drug Compounding, and Infusion Systems.
BAX closed at $26.41, up 2.4%, sitting above both its 50-day ($24.51) and 200-day ($21.51) moving averages, with the shorter average above the longer one. The GekkoIndex reads 54, placing the stock in the Neutral zone, down from a five-day change of -9.5. The price sits 3.6% above Gekko Fair Value of $25.50.
The next earnings date is 11 February 2027, 88 days away, outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in their respective windows. Seasonality over the next 20 trading days has averaged -1.2% across 5 years, with gains in 3 of them. Consensus among 7 analysts stands at 0 buy, 6 hold, 1 sell, with a consensus target of $27, implying 2.2% upside.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Baxter International scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed0 headwinds
Above 50 and 200-day
Close $25.81 is above the 50-day ($24.54) and 200-day ($21.64) averages, and the 50-day is above the 200-day.
See the chart56.1, Neutral
Reading 56.1 is in the Neutral zone.
See the GekkoIndex0.7% above
Price is within 5% of Gekko Fair Value (0.7% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 88 days
Next report Feb 11, 2027, 88 days away — outside a typical 20-trading-day hold.
See earnings+2.5% on average
From this point in the calendar, the next 20 trading days averaged +2.5% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Baxter International closed at $25.81 on Nov 13, 2026, +38.0% over the past year, inside a 52-week range of $15.73 to $30.00.
Use the left and right arrow keys to read daily values.
Put BAX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Baxter International makes a broad range of healthcare products used in treating serious and chronic conditions. Its offerings span dialysis care for kidney patients, intravenous fluids and infusion equipment, drug compounding and pharmacy services, nutrition therapies given outside normal eating, and surgical products used to control bleeding, seal tissue and limit adhesions during operations. It is also recognized for connected care systems that combine monitoring devices, software and communication tools used across hospitals and clinics.
The company reaches patients through hospitals, dialysis centers, nursing and rehabilitation facilities, doctors' offices, and home care settings. It sells through a mix of its own sales staff, independent distributors, drug wholesalers and specialty pharmacies, and it works with roughly 100 countries worldwide. Baxter also performs contract work for other pharmaceutical and biopharmaceutical firms, and has a partnership with Celerity Pharmaceutical focused on generic injectable and oncolytic drug development.
Baxter International was founded in 1931 and is headquartered in Deerfield, Illinois. Its shares are listed on the NYSE under the ticker BAX.
Baxter International’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 56.1, in the Neutral zone, up 0.9 points over five sessions.
Up 0.9 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 84 | +0.1% | +0.4% | ||
| Accumulation | 238 | −0.4% | −1.4% | ||
| Neutral (current zone) | 353 | 0.0% | −0.5% | ||
| Distribution | 26 | −1.3% | −1.9% | ||
| Selling | 1 | Too few readings yet | |||
Average BAX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Baxter International trades 0.7% above Gekko Fair Value of $25.62, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Baxter International shares are worth, recalculated every trading day.
$25.62
Gekko Fair Value, Nov 13, 2026
0.7% above fair value · About fair value
At the end of Aug 2026 the price was 4.3% below the estimate.
No open-market insider purchases were filed for Baxter International, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for BAX in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in BAX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Baxter International has been buying back its own shares.
From company filings.
0of the funds Gekko tracks hold BAX.
Baxter International reports on Feb 11, 2027, before the open (88 days away), and beat the EPS estimate in 6 of its last 8 reports.
Feb 11, 2027
Expected before the open, 88 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 29, 2026 | $0.58 est $0.52 | $2.98B est $2.91B | −9.7% |
| Jul 30, 2026 | $0.56 est $0.36 | $2.96B est $2.80B | +5.6% |
| Apr 30, 2026 | $0.36 est $0.31 | $2.70B est $2.62B | +1.8% |
| Feb 12, 2026 | $0.44 est $0.55 | $2.97B est $2.82B | −11.2% |
| Oct 30, 2025 | $0.69 est $0.60 | $2.84B est $2.82B | −17.6% |
| Jul 31, 2025 | $0.59 est $0.61 | $2.81B est $2.88B | −21.7% |
| May 1, 2025 | $0.55 est $0.48 | $2.63B est $2.59B | −1.5% |
| Feb 20, 2025 | $0.58 est $0.52 | $2.75B est $2.67B | +9.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Baxter International is $27.25, +5.6% from the last close, from 6 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 6 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 9 | Barclays | $23 | −10.9% |
| Nov 6 | Barclays | $23 | −10.9% |
| Oct 30 | Stifel Nicolaus | $25 | −3.1% |
| Oct 30 | Wells Fargo | $25 | −3.1% |
| Oct 30 | J.P. Morgan | $25 | −3.1% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Baxter International averaged +2.5% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.3% | 2 of 5 |
| Next 10 trading days | +1.6% | 4 of 5 |
| Next 15 trading days | −0.6% | 2 of 5 |
| Next 20 trading days | +2.5% | 3 of 5 |
| Next 30 trading days | +2.1% | 3 of 5 |
For scale, BAX’s typical 20-trading-day move in either direction is about 6.6%.
Baxter International’s market cap is $13.35B and revenue of $11.61B over the last twelve months.
Coverage of Baxter International this week reads positive: 6 positive, 0 neutral and 0 negative headlines.
Baxter International’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| ABTAbbott Laboratories | Neutral | 10.5% below |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
A peer links to its own page where one exists.
Baxter International’s market cap is $13.35B at the Nov 13, 2026 close of $25.81, with 517.3M shares outstanding.
The consensus analyst 12-month price target for Baxter International is $27.25, +5.6% from the last close. Of the 6 firms that rated the stock in the last 90 days, 0 rate it a buy, 5 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Baxter International is about fair value: the Nov 13, 2026 close of $25.81 is 0.7% above Gekko Fair Value of $25.62. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Baxter International is expected to report on Feb 11, 2027, before the market opens (88 days away). Analysts expect earnings of $0.60 per share on revenue of $3.09B. Baxter International beat the earnings estimate in 6 of its last 8 reports, moving 9.9% on average across the report.
Baxter International’s 52-week high is $30.00 and its 52-week low is $15.73; it closed at $25.81 on Nov 13, 2026, +38.0% over the past year. Over the last five years the shares peaked at $89.70 on Feb 9, 2022.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.